ArticleClinical and experimental medicine2025
Clinicopathologic predictors of renal response and survival in newly diagnosed multiple myeloma with renal injury: a retrospective study.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Infection incidence, timing, and predictors in newly diagnosed multiple myeloma: a real-world retrospective cohort study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Renal impairment (RI) is a common complication of multiple myeloma (MM), which is associated with poor prognosis. Here, we revealed the association between regular examination data and RI incidence, RI response and survival in newly diagnosed multiple myeloma (NDMM) patients. A retrospective analysis was conducted on the initial clinical data of 647 NDMM patients, comprising 193 patients (29.83%, 193/647) with RI and 454 (70.17%, 454/647) without RI at diagnosis. Logistic regression analyses, both univariate and multivariate, were performed to identify the independent influencing factors of RI with bootstrap techniques and resampling. The model used to predict the RI response was established using the support vector machine-recursive feature elimination (SVM-RFE) machine learning algorithms. Six variables identified by multi-factorial logistic regression analysis were independently associated with the incidence of RI, including the secreted monoclonal immunoglobulin of IgG type (33.16% vs. 52.64%), deregulated serum free κ/λ light chain (58.12% vs. 33.93%), elevated serum calcium (> 2.65 mmol/L, 31.61% vs. 11.01%), elevated urea (≥ 8.3 mmol/L, 92.23% vs. 20.26%), elevated uric acid (≥ 340 μmol/L, 74.61% vs. 35.46%), and ISS (International Staging System) stage of III (90.16% vs. 31.50%). The lactate dehydrogenase (≥ 250 U/L; HR = 1.786, P = 0.005) and CKD (chronic kidney disease) stage (G4-G5; HR = 5.830, P = 0.016) were the independent adverse factors of the overall survival of NDMM patients with RI. In addition, this study provided a model to predict the response of RI using 5 clinical features, including calcium, Durie-Salmon (DS) stage, creatinine level before treatment, age and gender. The sensitivity, specificity, area under the curve (AUC) and accuracy were 86.75%, 51.15%, 78.30% and 72.99% in the training group, while 79.31%, 52.94%, 72.40% and 69.57% in the validation group. In conclusion, this study clarified the relationship between clinicopathologic characteristics and the incidence of renal injury, response and survival of NDMM patients, supporting clinical decision-making, and offering significant clinical application value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.